Shilpa Medicare intimates of completion of USFDA inspection of its API facilities in Raichur, Karnataka
"We are in receipt of EIR (establishment inspection report) from the US Food and Drug Administration (USFDA) to our both API manufacturing facilities located at Raichur, Karnataka," Shilpa Medicare said in a BSE filing.
This inspection was carried out between January 16-19, 2018. The inspection has now been closed by the USFDA, it added.
USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)